Poteligeo® (mogamulizumab-kpkc) – New orphan drug approval
August 8, 2018 - The FDA announced the approval of Kyowa Kirin’s Poteligeo (mogamulizumab-kpkc) for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.
Top